Cargando…

The small GTPase RhoU lays downstream of JAK/STAT signaling and mediates cell migration in multiple myeloma

Multiple myeloma is a post-germinal center B-cell neoplasm, characterized by the proliferation of malignant bone marrow plasma cells, whose survival and proliferation is sustained by growth factors and cytokines present in the bone marrow microenvironment. Among them, IL-6 triggers the signal downst...

Descripción completa

Detalles Bibliográficos
Autores principales:	Canovas Nunes, Sara, Manzoni, Martina, Pizzi, Marco, Mandato, Elisa, Carrino, Marilena, Quotti Tubi, Laura, Zambello, Renato, Adami, Fausto, Visentin, Andrea, Barilà, Gregorio, Trentin, Livio, Manni, Sabrina, Neri, Antonino, Semenzato, Gianpietro, Piazza, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5811530/ https://www.ncbi.nlm.nih.gov/pubmed/29440639 http://dx.doi.org/10.1038/s41408-018-0053-z

Ejemplares similares

Prosurvival autophagy is regulated by protein kinase CK1 alpha in multiple myeloma
por: Carrino, Marilena, et al.
Publicado: (2019)

Inactivation of CK1α in multiple myeloma empowers drug cytotoxicity by affecting AKT and β-catenin survival signaling pathways
por: Manni, Sabrina, et al.
Publicado: (2017)

Protein Kinase CK1α Sustains B-Cell Receptor Signaling in Mantle Cell Lymphoma
por: Manni, Sabrina, et al.
Publicado: (2021)

Protein Kinase CK2 Inhibition Down Modulates the NF-κB and STAT3 Survival Pathways, Enhances the Cellular Proteotoxic Stress and Synergistically Boosts the Cytotoxic Effect of Bortezomib on Multiple Myeloma and Mantle Cell Lymphoma Cells
por: Manni, Sabrina, et al.
Publicado: (2013)

Glycogen Synthase Kinase-3 regulates multiple myeloma cell growth and bortezomib-induced cell death
por: Piazza, Francesco, et al.
Publicado: (2010)

NK cells and CD38: Implication for (Immuno)Therapy in Plasma Cell Dyscrasias
por: Zambello, Renato, et al.
Publicado: (2020)

Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity
por: Quotti Tubi, Laura, et al.
Publicado: (2013)

CK1α/RUNX2 Axis in the Bone Marrow Microenvironment: A Novel Therapeutic Target in Multiple Myeloma
por: Fregnani, Anna, et al.
Publicado: (2022)

Old and Young Actors Playing Novel Roles in the Drama of Multiple Myeloma Bone Marrow Microenvironment Dependent Drug Resistance
por: Manni, Sabrina, et al.
Publicado: (2018)

Actionable Strategies to Target Multiple Myeloma Plasma Cell Resistance/Resilience to Stress: Insights From “Omics” Research
por: Manni, Sabrina, et al.
Publicado: (2020)

Protein Kinase CK2 represents a new target to boost Ibrutinib and Venetoclax induced cytotoxicity in mantle cell lymphoma
por: Manni, Sabrina, et al.
Publicado: (2022)

P1279: INHIBITION OF PROTEIN KINASE CK2 AND BCL-2: A NOVEL THERAPEUTIC STRATEGY TO ANTAGONIZE MANTLE CELL LYMPHOMA CELL GROWTH
por: Manni, S., et al.
Publicado: (2022)

Targeting Protein Kinases in Blood Cancer: Focusing on CK1α and CK2
por: Spinello, Zaira, et al.
Publicado: (2021)

CK2β Regulates Hematopoietic Stem Cell Biology and Erythropoiesis
por: Quotti Tubi, Laura, et al.
Publicado: (2023)

Atypical RhoV and RhoU GTPases control development of the neural crest
por: Faure, Sandrine, et al.
Publicado: (2011)

Identification of the true hyperdiploid multiple myeloma subset by combining conventional karyotyping and FISH analysis
por: Barilà, Gregorio, et al.
Publicado: (2020)

CK2β-regulated signaling controls B cell differentiation and function
por: Quotti Tubi, Laura, et al.
Publicado: (2023)

Activating KIRs in Chronic Lymphoproliferative Disorder of NK Cells: Protection from Viruses and Disease Induction?
por: Zambello, Renato, et al.
Publicado: (2014)

A bone-based 3D scaffold as an in-vitro model of microenvironment–DLBCL lymphoma cell interaction
por: Ceccato, Jessica, et al.
Publicado: (2022)

Regulation and functions of RhoU and RhoV
por: Hodge, Richard G., et al.
Publicado: (2017)

Analysis of Rho GTPase expression in T-ALL identifies RhoU as a target for Notch involved in T-ALL cell migration
por: Bhavsar, Parag J., et al.
Publicado: (2012)

Insights Into Genetic Landscape of Large Granular Lymphocyte Leukemia
por: Teramo, Antonella, et al.
Publicado: (2020)

Neutropenia and Large Granular Lymphocyte Leukemia: From Pathogenesis to Therapeutic Options
por: Calabretto, Giulia, et al.
Publicado: (2021)

Correction to: Role of protein kinases CK1α and CK2 in multiple myeloma: regulation of pivotal survival and stress-managing pathways
por: Manni, Sabrina, et al.
Publicado: (2018)

Role of protein kinases CK1α and CK2 in multiple myeloma: regulation of pivotal survival and stress-managing pathways
por: Manni, Sabrina, et al.
Publicado: (2017)

Bendamustine plus rituximab is an effective first-line treatment in hairy cell leukemia variant: a report of three cases
por: Visentin, Andrea, et al.
Publicado: (2017)

The Importance of Alliance between Hematologists and Dentists: A Retrospective Study on the Development of Bisphosphonates Osteonecrosis of the Jaws (Bronj) in Multiple Myeloma Patients
por: Bacci, Christian, et al.
Publicado: (2021)

Subcutaneous immunoglobulins replacement therapy in secondary antibody deficiencies: Real life evidence as compared to primary antibody deficiencies
por: Cinetto, Francesco, et al.
Publicado: (2021)

Metabolic control of epigenetic rearrangements in B cell pathophysiology
por: Calciolari, Beatrice, et al.
Publicado: (2022)

Protein kinase CK2 is widely expressed in follicular, Burkitt and diffuse large B-cell lymphomas and propels malignant B-cell growth
por: Pizzi, Marco, et al.
Publicado: (2015)

Cross-talk between chronic lymphocytic leukemia (CLL) tumor B cells and mesenchymal stromal cells (MSCs): implications for neoplastic cell survival
por: Trimarco, Valentina, et al.
Publicado: (2015)

Lights and Shade of Next-Generation Pi3k Inhibitors in Chronic Lymphocytic Leukemia
por: Visentin, Andrea, et al.
Publicado: (2020)

Are T-LGL Leukemia and NK-Chronic Lymphoproliferative Disorder Really Two Distinct Diseases?
por: Zambello, Renato, et al.
Publicado: (2014)

Dominant cytotoxic NK cell subset within CLPD-NK patients identifies a more aggressive NK cell proliferation
por: Barilà, Gregorio, et al.
Publicado: (2018)

Treatment Induced Cytotoxic T-Cell Modulation in Multiple Myeloma Patients
por: Barilà, Gregorio, et al.
Publicado: (2021)

PAK4 promotes kinase-independent stabilization of RhoU to modulate cell adhesion
por: Dart, Anna E., et al.
Publicado: (2015)

In Chronic Lymphocytic Leukemia the JAK2/STAT3 Pathway Is Constitutively Activated and Its Inhibition Leads to CLL Cell Death Unaffected by the Protective Bone Marrow Microenvironment
por: Severin, Filippo, et al.
Publicado: (2019)

Identification of a miR-146b-Fas ligand axis in the development of neutropenia in T large granular lymphocyte leukemia
por: Mariotti, Barbara, et al.
Publicado: (2020)

STAT3 mutation impacts biological and clinical features of T-LGL leukemia
por: Teramo, Antonella, et al.
Publicado: (2017)

GRB2 couples RhoU to epidermal growth factor receptor signaling and cell migration
por: Zhang, Jin-San, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_gj98vph6ata3t7hcu2pm8oe1a4